Evidence map›Paper›PMID 37693880›Full record

ArticleThe Lancet regional health. Western Pacific2023

A community-based strategy to eliminate hepatitis C among people who inject drugs in Vietnam.

Nicolas Nagot, Nguyen Thanh Binh, Tran Thi Hong, Vu Hai Vinh, Catherine Quillet, Roselyne Vallo, Duong Thi Huong, Khuat Thi Hai Oanh, Nham Thi Tuyet Thanh, Delphine Rapoud and 14 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet regional health. Western Pacific, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 4 countries.

Nicolas NagotPathogenesis and Control of Chronic and Emerging Infections, Université de Montpellier, Inserm, Etablissement Français du Sang, Montpellier, France.
Nguyen Thanh BinhFaculty of Public Health, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
Tran Thi HongFaculty of Public Health, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
Vu Hai VinhInfectious and Tropical Diseases Department, Viet Tiep Hospital, Hai Phong, Vietnam.
Catherine QuilletPathogenesis and Control of Chronic and Emerging Infections, Université de Montpellier, Inserm, Etablissement Français du Sang, Montpellier, France.
Roselyne ValloPathogenesis and Control of Chronic and Emerging Infections, Université de Montpellier, Inserm, Etablissement Français du Sang, Montpellier, France.
Duong Thi HuongFaculty of Public Health, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
Khuat Thi Hai OanhCenter for Supporting Community Development Initiatives, Hanoi, Vietnam.
Nham Thi Tuyet ThanhCenter for Supporting Community Development Initiatives, Hanoi, Vietnam.
Delphine RapoudPathogenesis and Control of Chronic and Emerging Infections, Université de Montpellier, Inserm, Etablissement Français du Sang, Montpellier, France.
Bach Thi Nhu QuynhDepartment of Molecular Biology, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
Duc Quang NguyenFaculty of Public Health, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
Jonathan FeelemyerSchool of Global Public Health, New York University, New York, USA.
Laurent MichelCESP Inserm UMRS 1018, Paris Saclay University, Pierre Nicole Center, French Red Cross, Paris, France.
Peter VickermanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Hannah FraserPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Laurence WeissUniversité de Paris Cité, Department of Clinical Immunology, Hôpital Hôtel Dieu AP-HP, Paris, France.
Maud LemoineLiver Unit, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Karine LacombeSorbonne Université Inserm IPLESP, Hôpital St Antoine AP-HP, Paris, France.
Don Des JarlaisSchool of Global Public Health, New York University, New York, USA.
Pham Minh KhueFaculty of Public Health, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
Jean Pierre MolesPathogenesis and Control of Chronic and Emerging Infections, Université de Montpellier, Inserm, Etablissement Français du Sang, Montpellier, France.
Didier LaureillardPathogenesis and Control of Chronic and Emerging Infections, Université de Montpellier, Inserm, Etablissement Français du Sang, Montpellier, France.
DRIVE-C study group
Hai phong University Of Medicine and Pharmacy · VNInserm · FRNew York University · USUniversity of Bristol · GBHung Vuong Hospital · VNImperial College London · GBUniversité Paris Cité · FR

Funding

Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan · 1998 to 2026
$38.9M
NIDA NIH HHS P30 DA011041
6 · The paper itself

Abstract

Background: Towards hepatitis C elimination among people who inject drugs (PWID), we assessed the effectiveness of a strategy consisting of a community-based respondent-driven sampling (RDS) as wide screening, a simplified and integrated hospital-based care, and prevention of reinfection supported by community-based organisations (CBO), in Hai Phong, Vietnam. Methods: Adults who injected heroin were enrolled in a RDS survey implemented in two CBO premises. Rapid HIV and HCV tests were done on site, and blood was taken for HCV RNA testing. Those with detectable HCV RNA were referred with CBO support to three public hospitals for 12-week sofosbuvir/daclatasvir, plus ribavirin for patients with cirrhosis. Participants were followed-up 12 weeks post-treatment (SVR12) and 48 weeks after enrolment. The primary endpoint was the rate of undetectable HCV RNA participants at 48 weeks. Findings: Among the 1444 RDS survey participants, 875 had hepatitis C. Their median age was 41 years (IQR 36-47), 96% were males, 36% were HIV-coinfected. Overall, 686 (78.4%) started sofosbuvir/daclatasvirs, and 629 of the 647 (97.2%) patients tested at SVR12 were cured. At week 48 (581/608) 95.6% had undetectable HCV RNA, representing 66.4% of all PWID identified with hepatitis C. The reinfection rate after SVR12 was 4/100 person-years (95% CI: 2-7). Interpretation: Our strategy, involving CBO and addressing all steps from wide HCV screening to prevention of reinfection, stands as a promising approach to eliminate HCV among PWID in low and middle-income countries. Funding: France ANRS|MIE (#ANRS12380). The RDS survey was implemented with grants from the NIDA (#R01DA041978) and ANRS|MIE (#ANRS12353).

Indexed as

Community-based organisationsHepatitis CPeople who inject drugsRespondent-driven sampling

Identifiers

PMID37693880
PMCPMC10485672
OpenAlexW4378530545

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.